Skip to main content
Clinical Trials/NCT01398722
NCT01398722
Unknown
Phase 2

Study of the Relationship Between Intensive Insulin Therapy and Clinical Prognosis in Infants Undergoing Cardiac Surgery

Xijing Hospital1 site in 1 country800 target enrollmentAugust 2011
ConditionsCardiac Surgery

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Cardiac Surgery
Sponsor
Xijing Hospital
Enrollment
800
Locations
1
Primary Endpoint
All cause mortality
Last Updated
14 years ago

Overview

Brief Summary

The investigators sought to determine whether intensive insulin therapy can improve prognosis of infants undergoing cardiac surgery.

Detailed Description

Previous studies showed that tight blood glucose control with insulin during intensive care reduced morbidity and mortality of surgical and medical intensive care patients. Blood sugar control with intravenous insulin may improve prognosis of patients undergoing cardiac surgery. It is not clear what the best insulin regimen is or what is the best blood sugar target in these patients. So far, most of researches have focused on adult patients but little on infants. The current prospective, randomized, controlled study will assess the impact of intensive insulin therapy on the outcome of infants undergoing cardiac surgery. On admission, patients will be randomly assigned to either strict normalization of blood glucose ( 110-150 mg/dl) with intensive insulin therapy or the conventional approach, in which blood glucose levels are maintained between 150 and 180 mg/dl.

Registry
clinicaltrials.gov
Start Date
August 2011
End Date
July 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xijing Hospital

Eligibility Criteria

Inclusion Criteria

  • Infants underwent cardiac surgery with cardiopulmonary bypass

Exclusion Criteria

  • Therapy restricted upon admission
  • Preoperative liver or kidney disease or dysfunction
  • Preoperative coagulation disorder
  • Palliative operation or a second operation
  • Type 1 diabetes
  • Type 2 diabetes

Outcomes

Primary Outcomes

All cause mortality

Time Frame: one year

Secondary Outcomes

  • Cardiac Index(average 1 month during the hospitalization)
  • Biochemical markers of myocardial injury(troponin and creatine kinase MB)(average 1 month during the hospitalization)
  • Acute renal failure(average 1 month during the hospitalization)
  • Respiratory failure(average 1 month during the hospitalization)
  • ICU and hospital length of stay, and ICU readmissions(average 1 month during the hospitalization)
  • Stroke and reversible ischemic neurologic deficit(average 1 month during the hospitalization)
  • Inotropic Scores(average 1 month during the hospitalization)
  • Perioperative complications(average 1 month during the hospitalization)

Study Sites (1)

Loading locations...

Similar Trials